The primary aim of the study consists in testing the hypothesis that blockade of the RAS may decrease the risk of developing adverse effects in patients with benign IgAN.Such blockade would first achieved with unique pharmacological class then shifting to the association of the two classes as soon as ineffective blockade is documented MedDRA version: 9.1 Level: SOC Classification code 10038359 Term: Renal and urinary disorders
Conditions
Interventions
Product Name: Ramipril
Pharmaceutical Form: Tablet
INN or Proposed INN: Ramipril
CAS Number: 87333-19-5
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Product
Sponsors
AZIENDA OSPEDALIERA PROVINCIALE DI LECCO
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: ;Secondary Objective: ;Primary end point(s): | — |
Countries
Italy
Outcome results
None listed